Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.

	Dec '20	Dec '21	Dec '22	Dec '23
revenue				6.00M -
cost of revenue		16.13K -	27.36K 69.60%	27.36K 0%
gross profit		-16.13K -	-27.36K 69.60%	5.97M 21,937.09%
selling and marketing expenses	445.13K -
general and administrative expenses	668.70 -	2.31M 345,651.76%	4.85M 109.64%	7.83M 61.61%
selling general and administrative expenses	445.80K -	2.31M 418.63%	4.85M 109.64%	7.83M 61.61%
research and development expenses	248.97K -	2.54M 921.06%	4.94M 94.23%	5.50M 11.42%
other expenses		16.13K -	27.36K 69.60%	639.37K 2,236.77%
cost and expenses	694.77K -	4.87M 601.00%	9.81M 101.46%	13.36M 36.18%
operating expenses	694.77K -	4.87M 601.00%	9.81M 101.46%	13.34M 35.91%
interest expense	38.98K -		2.43M -
ebitda	-694.77K -	-4.88M 601.77%	-9.78M 100.68%	-7.33M 25.06%
operating income	-694.77K -	-4.87M 601.00%	-9.81M 101.46%	-7.36M 24.99%
depreciation and amortization	704.65 -	-5.35K 859.10%	27.36K 611.52%	27.36K 0%
total other income expenses net	-38.42K -	-21.48K 44.09%	-2.43M 11,225.00%	96.18K 103.95%
income before tax	-733.20K -	-4.89M 567.19%	-12.24M 150.31%	-7.26M 40.68%
income tax expense	-704.65 -	-21.48K 2,948.59%	2.43M 11,425.00%	723.85K 70.25%
net income	-733.20K -	-4.87M 564.26%	-14.68M 201.37%	-7.99M 45.58%
weighted average shs out	9.68M -	9.68M 0%	9.95M 2.77%	10.16M 2.17%
weighted average shs out dil	9.68M -	9.68M 0%	9.95M 2.77%	10.16M 2.17%
eps	-0.08 -	-0.50 560.50%	-1.48 196%	-0.79 46.62%
epsdiluted	-0.08 -	-0.50 560.50%	-1.48 196%	-0.79 46.62%

NASDAQ:COYA

Coya Therapeutics, Inc.

Last Close

5.90

30/08 20:00

Market Cap

102.29M

Beta: -

Volume Today

4.79K

Avg: 49.57K

PE Ratio

−4.94

PFCF: −5.88

Preview